Sun Pharmaceutical Industries Limited will report its June-quarter earnings on Tuesday and analysts expect the drugmaker to report a single-digit profit growth this time around.
- Revenue growth is seen around 10 percent while EBITDA could rise by around 8.5 percent, with margins stable at around 21-22 percent and profit growth in single-digit around 7 percent.
- In terms of geographies what would lead the revenue growth is definitely the US business because last quarter the company had alluded to a onetime supply opportunity which started in Q4. So the street is anticipating that to continue into Q1. However, on QoQ basis, there could be some amount of a decline around 3-4 percent on QoQ basis or maybe a flattish performance for the US business.